Literature DB >> 16282847

Characterizations of long-term anxiolytic benzodiazepine prescriptions in veteran patients.

John A Hermos1, Melissa M Young, Elizabeth V Lawler, Margaret R Stedman, David R Gagnon, Louis D Fiore.   

Abstract

To characterize long-term prescriptions for commonly prescribed anxiolytic benzodiazepines to veteran patients and to identify factors associated with high daily doses, we analyzed the linked pharmacy and administrative databases from New England Veterans Healthcare System (VISN 1). We analyzed treatment episodes of 3 months or longer with the 4 most commonly prescribed agents: alprazolam, clonazepam, diazepam, and lorazepam. Descriptive statistics and univariate and multivariate analyses described the sample and tested associations of pharmacological and clinical variables for patients prescribed the top 5% of average daily doses ("high-dose" prescriptions). From 16,630 full or partial treatment episodes for all 4 agents analyzed within a 42-month window, average daily doses were predominantly moderate, age-sensitive, and stable; refill lag intervals were short. Patients on "high-dose" prescriptions for the 4 agents combined, compared with "middle quartile" dose prescriptions, in adjusted analyses, were younger, more likely to have posttraumatic stress disorder (odds ratio [OR], 2.6; 95% confidence interval [CI], 2.17-3.13), substance abuse (OR, 1.50; 95% CI, 1.25-1.80), and anxiety (OR, 1.33; 95% CI, 1.11-1.60) and were more likely to be receiving concurrent oxycodone/acetaminophen (OR, 2.05; 95% CI, 1.64-2.56), anxiolytic benzodiazepine (OR, 1.51; 95% CI, 1.12-2.03), antidepressant (OR, 2.15; 95% CI, 1.80-2.58), and neuroleptic (OR, 2.03; 95% CI, 1.69-2.44) prescriptions. These results indicate that veteran patients prescribed anxiolytic benzodiazepines typically receive modest, nonincreasing doses over long-term treatment episodes. However, those on the highest average daily doses, typically more than recommended guidelines, are more likely to have clinical diagnoses and concurrent prescriptions for psychoactive medications indicative of more complex and, perhaps, problematic management.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16282847     DOI: 10.1097/01.jcp.0000185430.10053.1e

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  3 in total

1.  Warnings Unheeded:The Risks of Co-Prescribing Opioids and Benzodiazepines.

Authors:  Shanna Babalonis; Sharon L Walsh
Journal:  Pain Clin Updates       Date:  2015-11

2.  Does accreditation improve pro re nata benzodiazepines administration in psychiatric inpatients? Pre-post accreditation medical record comparison.

Authors:  Mohammed Abdullah Al-Sughayir
Journal:  Int J Ment Health Syst       Date:  2017-02-02

Review 3.  Benzodiazepine high-doses: The need for an accurate definition.

Authors:  Jean-Marc Cloos; Christopher Y S Lim Cow; Valéry Bocquet
Journal:  Int J Methods Psychiatr Res       Date:  2021-07-31       Impact factor: 4.035

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.